Safety of lornoxicam in G-6-PDH deficiency
Abstract
Objective: To assess the safety of lornoxicam in subjects with G-6-PDH deficiency. Methods: Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases. Results: In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age ± SD, 54.3 years ± 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment. Conclusions: Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases.
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.